Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acetylamino-acetic acid
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
Acetylamino-Acetic Acid is a small molecule compound classified as an N-acyl-alpha amino acid. Its chemical formula is C4H7NO3 and it has a molecular weight of approximately 117.1 g/mol[1]. It is also known as 2-acetamidoacetic acid or aceturic acid. The compound is considered experimental and does not have any approved medical indications or clinical trial activity reported[1][3]. Structurally, it can be described as glycine with an acetyl group attached to the amino group (N-acetylglycine). There are no well-documented mechanisms of action or therapeutic uses for this compound in humans.
- Other names
- 2-acetamidoacetic acidaceturic acidglycine, N-acetyl-N-acetylglycine
Beyond the preview
Go deeper on acetylamino-acetic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acetylamino-acetic acid.